Foster City, CA, United States of America

Bei Li

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 33(Granted Patents)


Location History:

  • San Diego, CA (US) (2011 - 2014)
  • Foster City, CA (US) (2016 - 2024)

Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Bei Li

Introduction

Bei Li, an accomplished inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals, particularly through his innovative research. With a total of four patents to his name, Bei Li's work is centered around developing solutions for complex medical challenges.

Latest Patents

Among his latest patents, Bei Li has introduced spirocyclic aminoquinolones as GSK-3 inhibitors. These compounds are notable for their potential to provide therapeutic benefits in the prevention, amelioration, or treatment of diseases mediated by GSK-3 inhibitors. The formula includes specific structures where X can be either O or NR, and A is defined as bond or substituted/unsubstituted C-Calkylene. This innovative composition demonstrates the utility of spirocyclic aminoquinolones in addressing critical health issues.

Career Highlights

Currently, Bei Li is associated with Kyorin Pharmaceutical Co., Ltd., a company known for its commitment to advancing medical technology and drug development. His dedication to research and innovation within this company's framework has positioned him as a key figure in his field.

Collaborations

Throughout his career, Bei Li has collaborated with esteemed colleagues such as Anna Katrin Szardenings and Oana Cociorva. These partnerships have fostered a productive environment for innovation, enabling the team to explore and develop cutting-edge pharmaceutical solutions.

Conclusion

In summary, Bei Li's contributions to the innovation landscape illustrate the profound impact of dedicated research and collaboration in addressing complex medical challenges. As he continues his work with Kyorin Pharmaceutical Co., Ltd., the potential for his inventions to revolutionize treatment options remains promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…